,,accccchhhhh,,,toinv,,,,,its more like water under the fridge!!,,, hahaha,,,,and no matter what comes down to the tube to us Nov. 16, the timeline/s given by DM around future activity needs to be atleast doubled and the cost given a factor of possibly 5X,,,,,,,,,,its just the way management has performed,,,,,,,,,,as they seem not to be really in the know at the planning stage,,,along with this,,,,the market is very much aware of missed timelines and cost estimates,,,,,,,,,,and its a shorts dream to have such volitility and a history of missing the mark,,,,,,

,,,,,and fzzjr,,it wasnt a history lesson,,it was simply a rehash around the lack of understanding of time and costs by management on the BoM trial,,,,thats all,,,and I personally dont see anything changing near term,,,,DM should possibly have not been so greedy in past and licensed one or more of these molecules to partners or pharma who have deep pockets and who might have already had one approved by now,,,,,thus,,,,,opening the gate for future approvals,,,,,,do we need to lock up all the hundreds of molecules,,,,that is hundreds!!!,,just a thought,,,